Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario La Fe (21)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  3. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  4. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  5. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

    Annals of Hematology

  6. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

  3. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  4. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

  5. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  3. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

  4. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea

    Leukemia, Vol. 35, Núm. 2, pp. 623-627

  2. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Leukemia, Vol. 34, Núm. 8, pp. 2125-2137

  2. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

    Bone Marrow Transplantation, Vol. 55, Núm. 3, pp. 641-648

2018

  1. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

    Leukemia